PMID

Data

Article Title

Organization

Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Muscarinic M(3) receptor antagonists with (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Design, synthesis, and discovery of a novel CCR1 antagonist.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

A potent, long-acting, orally active (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Stereoselective synthesis of a new muscarinic M3 receptor antagonist, J-104129.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories